For research use only. Not for therapeutic Use.
Ulenistamab (PBP1510) is a first-in-class hunamised IgG1 monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research[1].
Ulenistamab (PBP1510) suppresses the proliferation of the PC cell lines (CFPAC-1 and BxPC-3). The migration and invasion of PC cell lines is significantly reduced[1].
Pharmacokinetic (PK) characteristics and immunogenicity of PBP1510 (up to 20 mg/kg), are examined in single dose studies in 6 monkeys. In monkey studies, a dose-proportional increase in systemic exposure was observed at low and high doses[1].
| Catalog Number | I042129 |
| CAS Number | 2415259-90-2 |
| Purity | ≥95% |
| Reference | [1]. Kedar Diwakar Mandakhalikar, et al. First-in-class monoclonal antibody (mAb) PBP1510 targeting pancreatic adenocarcinoma upregulated factor (PAUF) for pancreatic cancer (PC) treatment: Preclinical perspectives. Journal of Clinical Oncology 2022 40:16_suppl, e16274-e16274. |
